Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) has been given an average rating of “Reduce” by the twelve research firms that are covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $8.20.
Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Thursday, October 15th.
Read Our Latest Report on Fulcrum Therapeutics
Institutional Trading of Fulcrum Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new stake in Fulcrum Therapeutics during the second quarter valued at approximately $32,297,000. Bank of New York Mellon Corp acquired a new stake in Fulcrum Therapeutics in the 2nd quarter valued at $566,000. Siren L.L.C. lifted its stake in Fulcrum Therapeutics by 20.5% in the 1st quarter. Siren L.L.C. now owns 2,350,000 shares of the company’s stock valued at $18,024,000 after purchasing an additional 400,000 shares during the last quarter. Nantahala Capital Management LLC bought a new stake in shares of Fulcrum Therapeutics during the second quarter worth approximately $20,038,646. Finally, Bank of America Corp DE acquired a new position in Fulcrum Therapeutics in the second quarter valued at about $3,817,000. Institutional investors own 89.83% of the company’s stock.
Fulcrum Therapeutics Price Performance
NASDAQ FULC opened at $3.70 on Wednesday. The business has a fifty day moving average of $3.77 and a 200-day moving average of $5.99. Fulcrum Therapeutics has a fifty-two week low of $2.83 and a fifty-two week high of $15.74.
Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) last announced its earnings results on Thursday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10). Sell-side analysts forecast that Fulcrum Therapeutics will post -0.60 EPS for the current year.
Fulcrum Therapeutics Company Profile
Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for genetically driven diseases. The company’s research approach is based on selectively modulating gene expression to address the underlying biology of disease rather than targeting individual symptoms.
Fulcrum’s lead investigational program is losmapimod, an oral small-molecule therapy being developed for facioscapulohumeral muscular dystrophy (FSHD), a rare and progressive genetic muscle disorder.
See Also
- Five stocks we like better than Fulcrum Therapeutics
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
- Charging Ahead: Solid Power’s Pilot Line Leaves the Lab
Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
